In line with its commitment to help address the world’s most pressing health care issues, and improve and save more lives, Ethicon, a medical device company of the Johnson & Johnson family of companies, today announced the completion of its acquisition of NeuWave Medical, Inc., a privately held medical device company that manufactures and markets minimally invasive soft-tissue microwave ablation systems. This acquisition is consistent with the Johnson & Johnson Medical Devices’ strategy of advancing innovation and investing in areas of unmet medical needs such as surgical oncology.
“Currently, there are limited treatment options for soft-tissue, non-resectable lesions,” said Michael del Prado, Company Group Chairman of Ethicon. “Together with NeuWave Medical, Ethicon can bring minimally invasive treatment options to make a difference for patients around the world. This is especially important for patients who may not be medically eligible for traditional surgery. We can now offer physicians and patients more choice in treatment options for soft-tissue lesions.”
NeuWave Medical’s products are currently used by physicians in over half of the top cancer centers in the United States. NeuWave Medical’s Certus® 140 ablation system’s high-powered computer and intuitive touchscreen interface enables activation of single or simultaneous multiple probe procedures for patients with soft-tissue lesions. This allows physicians to effectively tailor ablations for lesions of varying shapes and sizes. NeuWave Medical’s probe family includes conventional probes and the only Precision™ PR probe to limit the ablation length, allowing precise and controlled ablations.
Read more at PRNewswire.